Tauns Laboratories (TSE:197A) LT-Debt-to-Total-Asset: 0.29 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:197A Tauns Laboratories Inc TSE:197A
14 GF Score
Price 円484.00
! 6 Warning Signs
View Full Analysis

What is Tauns Laboratories LT-Debt-to-Total-Asset?

Tauns Laboratories TSE:197A -0.82% 14 LT-Debt-to-Total-Asset is 0.29 as of Dec. 2025. GuruFocus rates TSE:197A with a GF Score™ of 14/100. The stock has 6 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Tauns Laboratories's long-term debt to total assests ratio for the quarter that ended in Dec. 2025 was 0.29.

Tauns Laboratories's long-term debt to total assets ratio increased from Dec. 2024 (0.22) to Dec. 2025 (0.29). It may suggest that Tauns Laboratories is progressively becoming more dependent on debt to grow their business.

Tauns Laboratories  (TSE:197A) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Tauns Laboratories LT-Debt-to-Total-Asset Related Terms

Tauns Laboratories LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Tauns Laboratories's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tauns Laboratories LT-Debt-to-Total-Asset Chart

Tauns Laboratories Annual Data
Trend Jun22 Jun23 Jun24 Jun25
LT-Debt-to-Total-Asset
0.15 0.12 0.15 0.24

Tauns Laboratories Quarterly Data
Jun22 Jun23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.22 0.24 0.34 0.29 0.30
TSE:197A
14GF Score
Tauns Laboratories Inc TSE:197A
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tauns Laboratories LT-Debt-to-Total-Asset Calculation

Tauns Laboratories's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Jun. 2025 is calculated as

LT Debt to Total Assets (A: Jun. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Jun. 2025 )/Total Assets (A: Jun. 2025 )
=8809.081/36515.294
=0.24

Tauns Laboratories's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (Q: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2025 )/Total Assets (Q: Dec. 2025 )
=12868.088/44198.627
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.29 mean?
Tauns Laboratories (TSE:197A) has a LT-Debt-to-Total-Asset of 0.29 as of Dec. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Tauns Laboratories and its competitors.
Is Tauns Laboratories' LT-Debt-to-Total-Asset too high?
Tauns Laboratories' current LT-Debt-to-Total-Asset is 0.29. Overall, Tauns Laboratories has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Tauns Laboratories' LT-Debt-to-Total-Asset compare to ISRG and BDX?
Tauns Laboratories' LT-Debt-to-Total-Asset of 0.29 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Medical Devices & Instruments company?
A good LT-Debt-to-Total-Asset depends on the Medical Devices & Instruments industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Tauns Laboratories and its competitors. Tauns Laboratories's current LT-Debt-to-Total-Asset is 0.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tauns Laboratories stock overvalued right now?
Tauns Laboratories (TSE:197A) has a current LT-Debt-to-Total-Asset of 0.29. The current LT-Debt-to-Total-Asset is 0.29. Tauns Laboratories' overall GF Score™ is 14/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Tauns Laboratories (TSE:197A), the current LT-Debt-to-Total-Asset is 0.29 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tauns Laboratories Business Description

Address 761-1 Kamishima Izunokuni-shi, Shizuoka, JPN, 410-2325
Tauns Laboratories Inc is engaged in development, manufacture and sales of in vitro diagnostics and research reagents. Its product include Capilia Flu Neo, Capilia Adeno Neo, Capilia RSV Neo, Capilia hMPV, etc.
14GF Score

Get the complete analysis for TSE:197A

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円484.00
Price